F
Fabrice Barlesi
Researcher at Aix-Marseille University
Publications - 666
Citations - 36214
Fabrice Barlesi is an academic researcher from Aix-Marseille University. The author has contributed to research in topics: Lung cancer & Medicine. The author has an hindex of 64, co-authored 582 publications receiving 25403 citations. Previous affiliations of Fabrice Barlesi include Institut Gustave Roussy & Nord University.
Papers
More filters
Journal ArticleDOI
ALK-rearranged non-small cell lung cancers: how best to optimize the safety of crizotinib in clinical practice?
Nicolas Girard,Clarisse Audigier-Valette,Alexis B. Cortot,Bertrand Mennecier,Didier Debieuvre,David Planchard,Gérard Zalcman,Denis Moro-Sibilot,Jacques Cadranel,Fabrice Barlesi +9 more
TL;DR: Practical measures are proposed, which are mostly derived from the recommendations given to the investigators of the PROFILE 1001, 1005, 1007 and 1014 trials and are based on experience and scientific findings regarding the management of frequent crizotinib-related adverse events.
Journal ArticleDOI
MA07.05 Immune Checkpoint Inhibitor (ICPi) Re-Challenge: Outcomes Analysis in a French National Cohort of Non-Small-Cell Lung Cancer (NSCLC) Patients
Elisa Gobbini,Anne-Claire Toffart,Maurice Pérol,Jean-Baptiste Assié,Michael Duruisseaux,D. Coupez,Radj Gervais,Virginie Westeel,Myriam Delaunay,Florian Guisier,Remi Veillon,Valérie Gounant,E. Giroux Leprieur,F.R. Vanel,N. Chaabane,Eric Dansin,H. Babey,Chantal Decroisette,Fabrice Barlesi,Nicolas Girard,Pierre Fournel,Laura Mezquita,Youssef Oulkhouir,A. Canellas,B. Duchemann,Olivier Molinier,D. Moro-Sibilot,M. Giaj Levra +27 more
Journal ArticleDOI
Clinical Efficacy of atezolizumab (atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: Results from the randomized OAK study
Achim Rittmeyer,Shirish M. Gadgeel,Marcin Kowanetz,Wei Zou,Fred R. Hirsch,Keith M. Kerr,David R. Gandara,Fabrice Barlesi,Kwan Park,Mark McCleland,Hartmut Koeppen,Marcus Ballinger,Alan Sandler,Priti S. Hegde +13 more
Journal ArticleDOI
Randomized Phase II Trial Evaluating Treatment with EGFR-TKI Associated with Antiestrogen in Women with Nonsquamous Advanced-Stage NSCLC: IFCT-1003 LADIE Trial.
Julien Mazieres,Fabrice Barlesi,Isabelle Rouquette,Olivier Molinier,Benjamin Besse,Isabelle Monnet,Clarisse Audigier-Valette,Anne-Claire Toffart,Patrick Aldo Renault,Séverine Fraboulet,Sandrine Hiret,Bertrand Mennecier,Didier Debieuvre,Virginie Westeel,Philippe Masson,Anne Madroszyk-Flandin,Eric Pichon,Alexis B. Cortot,E. Amour,Franck Morin,Gérard Zalcman,Denis Moro-Sibilot,Pierre Jean Souquet +22 more
TL;DR: Adding fulvestrant to EGFR-TKI is feasible, but not associated with prolonged PFS regardless of EGFR status, which does not support its future development in an unselected population.
Journal ArticleDOI
Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: A contemporary clinical practice patterns study.
Luis Paz-Ares,Adam Gondos,D.A. Saldana,Marlene Thomas,Céline Mascaux,Lukas Bubendorf,Fabrice Barlesi +6 more
TL;DR: In this paper , the authors describe real-world use and clinical features of next-generation sequencing (NGS) and other non-NGS testing technologies in patients with advanced non-small cell lung cancer (aNSCLC).